ALEXANDRIA, Va., Jan. 20 -- United States Patent no. 12,527,841, issued on Jan. 20, was assigned to Novartis AG (Basel, Switzerland).
"Fibroblast growth factor-21-Fc fusion proteins" was invented by Brian R. Boettcher (Winchester, Mass.), Shari Lynn Caplan (Lunenburg, Mass.), Douglas S. Daniels (Arlington, Mass.), Norio Hamamatsu (Belmont, Mass.), Stuart Licht (Cambridge, Mass.) and Stephen Craig Weldon (Leominster, Mass.).
According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated ...